TruCan™ Ultra CIV H3N2/H3N8 vaccine

Search documents
Elanco Animal Health Incorporated (ELAN) Joins S&P MidCap 400 Following Strong Q2 Growth and Product Ramp-Up
Yahoo Finance· 2025-09-23 23:10
In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Elanco Animal Health Incorporated is one of them. Elanco Animal Health Incorporated (NYSE:ELAN), a global leader in veterinary pharmaceuticals and biologics, continues to advance its mission of improving animal health and food safety through innovation and sustainability. Serving veterinarians, farmers, and pet owners worldwide, the company leverages nearly 70 years of expertise to deliver solutions fo ...
10 Best Pharma Stocks to Buy According to Billionaires
Insider Monkey· 2025-09-21 13:29
Core Insights - President Trump has demanded major pharmaceutical companies to lower drug prices to "most favored nation" levels by September 29, prompting a response from the industry [1][2] - The administration has not specified the actions it may take if companies do not comply, but has indicated a willingness to use all available measures to protect American families from high drug prices [2] - A total of 17 large pharmaceutical companies received letters from the government, instructing them to sell drugs directly to consumers, bypassing pharmacy benefit managers [3] Company Highlights - **Jazz Pharmaceuticals plc (NASDAQ:JAZZ)**: - Ranked 10th among the best pharmaceutical stocks, with 10 billionaire holdings [8] - Recently received FDA accelerated approval for Modeyso, the first therapy for a rare CNS cancer, showing a 22% overall response rate in trials [9] - Focused on rare oncology indications and has ongoing trials for other promising drugs [10][11] - **Elanco Animal Health Incorporated (NYSE:ELAN)**: - Also ranked 9th with 10 billionaire holdings, recognized for its leadership in veterinary pharmaceuticals [12] - Joined the S&P MidCap 400 Index in September 2025, reflecting increased investor confidence [13] - Reported double-digit organic growth in Q2 2025 and has a strong innovation pipeline with six potential blockbuster products expected by year-end [14][15]